Estuary Biotherapeutics launches with $103 million to advance EST-201 and EST-101 gene therapies targeting PKD1 and PKD2 mutations in ADPKD.
Written By: Rishabh Sonawane, PharmD
Reviewed By: Pharmacally Editorial Team
Estuary Biotherapeutics has debuted with $103 million in committed financing to advance two investigational gene therapy programs targeting autosomal dominant polycystic kidney disease (ADPKD), an inherited disorder that progressively damages the kidneys. The company plans to advance EST-201, targeting PKD2 mutations, and EST-101, targeting PKD1 mutations, into clinical testing in 2027 and 2028, respectively, with the long-term goal of halting or reversing established disease.
Gene Therapies Target the Genetic Drivers of ADPKD
ADPKD is characterized by the progressive growth of fluid-filled cysts in both kidneys. As cysts enlarge, they damage surrounding tissue and impair kidney function, potentially leading to kidney failure and the need for dialysis or transplantation. Available treatments can slow disease progression in some patients, but reversing established structural damage remains an unmet clinical need.
Estuary’s approach builds on research by its scientific co-founders, Stefan Somlo and Michael Caplan of Yale School of Medicine. Somlo demonstrated in mouse models that restoring polycystin expression could reverse structural and functional features of established cystic kidney disease. Caplan subsequently showed that a compact functional region of polycystin-1 (PC1) could suppress cystic disease in mice, supporting a gene therapy strategy for PKD1-associated ADPKD.
The findings provide the preclinical rationale for targeting the underlying genetic defects rather than only the downstream processes that contribute to cyst formation.
Two Programs Address the Most Common Genetic Subtypes
Estuary’s lead candidates target the two principal genetic causes of ADPKD:
EST-201: An adeno-associated virus (AAV)-based gene therapy delivering full-length PKD2. The company expects to begin clinical evaluation in patients with PKD2 mutations in 2027.
EST-101: An AAV-based gene therapy delivering a compact functional region derived from PC1 for patients with PKD1 mutations. Clinical evaluation is anticipated in 2028.
The proteins encoded by PKD1 and PKD2, PC1 and polycystin-2 (PC2), work together in kidney cell biology. Disruption of their function contributes to cyst formation and progressive tissue damage.
Both programs use local kidney administration to deliver genetic material to kidney epithelial cells, with the goal of restoring functional polycystin protein across the nephron. Kidney-directed delivery could limit exposure to other organs and potentially reduce some risks associated with systemic AAV administration.
$103 Million Financing to Support Clinical Development
Estuary launched with $103 million in total committed financing, comprising a $93 million Series A led by RA Capital Management and a previously raised $10 million seed round co-led by 4BIO Capital and GV. Series A participants also included Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, the National Kidney Foundation Innovation Fund and a family office connected to an individual living with ADPKD.
The proceeds will support the advancement of EST-201 and EST-101 through clinical proof of concept and further development of the company’s kidney-targeting platform. Estuary also plans to expand its pipeline into other monogenic and common kidney diseases.
Clinical Translation Remains the Key Test
Chief executive Wayne Sackett identified delivery as a major obstacle to developing gene therapies for kidney disease. The company’s strategy combines the preclinical disease-reversal findings with localized administration to address this challenge.
However, neither program has yet demonstrated clinical safety or efficacy in humans. The available evidence supporting disease reversal comes from preclinical research, and the ability to achieve sufficient kidney-wide gene delivery, restore protein function and produce durable clinical benefits remains unproven.
The anticipated clinical entries of EST-201 in 2027 and EST-101 in 2028 will mark important development milestones. Subsequent studies will need to determine whether treatment can meaningfully improve kidney function, reduce cyst burden or alter the long-term course of ADPKD.
If the preclinical findings translate into patients, the programs could offer a therapeutic approach distinct from existing treatments that primarily slow progression. Their clinical significance will depend on demonstrating durable benefit alongside an acceptable safety profile.
Reference
Estuary Biotherapeutics Launches with $103 Million to Develop Targeted Gene Therapies for Kidney Disease, Estuary Biotherapeutics, 16 October 2026
About the Writer
Rishabha Sonawane, B.Pharm (LinkedIn) is healthcare writer with a strong interest in medical writing, regulatory affairs, clinical research, and AI-driven drug discovery. He has completed specialized training from the NIH and ICMR in clinical pharmacology, clinical research, and scientific writing. Passionate about evidence-based healthcare communication, he focuses on translating complex scientific research into clear, accurate, and engaging medical content.